anti-CD3/anti-glycan bispecific T-cell engager-armed T cells (GlycoNex/Taipei Medical University)

N/A

Report date: 2026/03/19 16:53:48

Base Information

Drug Nameanti-CD3/anti-glycan bispecific T-cell engager-armed T cells (GlycoNex/Taipei Medical University)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > T cell engagers
Mechanisms of ActionT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesGlyconex Inc
China Registration ClassN/A

Develop Information

Active CompaniesGlyconex IncTaipei Medical University
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A